Abstract:Background and Aim: Long-term lamivudine treatment for chronic hepatitis B virus (HBV) infection induces the emergence of lamivudine resistant HBV YMDD mutant strains. The aim of the present study was to observe the clone evolution of YMDD wild type and mutant strains in pretreatment and post-treatment samples during lamivudine therapy and analyze their clinical significance. Methods: Ten serum samples (five before and five after 48 weeks of therapy) obtained from five patients chronically infected with HBV and treated with lamivudine were studied. Part of the HBV polymerase gene flanking the YMDD motif was sequenced after polymerase chain reaction (PCR) amplification. Meanwhile, 20-24 clones were selected at random from each sample and YMDD wild type and mutant strains were detected by real-time fluorimetry PCR established in our laboratory. Results: The YMDD mutants were not detectable in all five patients before treatment and were found in four patients after 48 weeks of therapy by sequencing directly on PCR products. Analysis of individual clones showed that the ratios of mutant strains in each of the five patients were 0, 9.5, 0, 4.5 and 5.6%, respectively, before therapy and 100, 100, 65, 100 and 0%, respectively, after 48 weeks of therapy. M552I was detected before therapy in one patient but M552V became the domain strain after therapy. Until 52 weeks of therapy, serum HBV DNA and alanine aminotransferase (ALT) breakthrough were found in two of the four patients with YMDD mutations. The fifth patient experienced breakthrough of ALT but HBV DNA remained undetectable. Conclusions: The mutant strains of YMDD motif of HBV polymerase could be found in patients before lamivudine treatment, indicating that antiviral therapy allows the rapid selection of resistant strains. The replication ability of the M552V mutant strain might be stronger than that of the M552I mutant strain. (C) 2003 Blackwell Publishing Asia Pty Ltd.

P.038 Differences of Ymdd Mutational Patterns, Pre-Core/core Promoter Mutations, Serum Viral Loads in Lamivudine-Resistant Hepatitis B Genotypes B and C

Correlation of the Occurrence of YMDD Mutations with HBV Genotypes, HBV-DNA Levels, and HBeAg Status in Chinese Patients with Chronic Hepatitis B During Lamivudine Treatment

Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C

A Real-Time PCR Method Formonitoring YMDD Motif Mutations Associated with Lamivudine Resistance in Patients with HBVinfection

Application of PCR‐LDR‐nucleic Acid Detection Strip in Detection of YMDD Mutation in Hepatitis B Patients Treated with Lamivudine

Detecting of the Hepatic Fibrotic Indexes and Serous Markers from Patients with Chronic Hepatitis B (chb)and Variation of HBV DNA YMDD

Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy.

Analysis of Hepatitis B Virus Genotype, Virus Loads, Pre-Core/core Promoter Region of Nucleotide Sequence in Lamivudine-Resistant Hepatitis B Virus in Vivo

Dynamic Changes of Hepatitis B Virus Polymerase Gene Including YMDD Motif in Lamivudine-Treated Patients with Chronic Hepatitis B

Dynamics of hepatitis B virus variations during lamivudine treatment

Analysis of YMDD Mutants in Hepatitis B Virus Infected Patients with Lamivudine Therapy by Restriction Fragment Length Polymorphism (RFLP) of the PCR Products

Mutations in the hepatitis B virus polymerase gene associated with lamivudine therapy

Reverse Line Probe Hybridization Assay for Detection of Lamivudine-Resistant Chronic Hepatitis B Virus

Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus

Polymerase region mutations and hepatitis B virus genotypes in chronic hepatitis B patients with poor response to lamivudine

[Variants and Quasispecies of Reverse Transcriptase Region in Polymerase Gene of Hepatitis B Virus During Lamivudine Treatment].

Simultaneous Detection of Two Major Lamivudine-Resistant Mutants Using Competitively Differentiated-Pcr.

A Nanoscale Mutation-Sensitive On/Off Switch Based Assays for the Detection of Hepatitis B Virus Lamivudine-Resistant Mutations

Detection and Analysis of the New Kind of G743C and G743A Point Mutation of HBV P Gene in Hepatitis B Virus Infected Patients Resistant to Lamivudine

Early Changes of Hepatitis B Virus Quasispecies During Lamivudine Treatment and the Correlation with Antiviral Efficacy.

Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy.